Abstract: A method for treating a disorder characterized by salt retention, fluid retention, and combinations thereof. A method for determining the presence of or the progression of a disorder characterized by salt retention, fluid retention, salt loss, fluid loss, and combinations thereof. An immunoassay kit for detecting a level of prouroguanylin in a sample.
Type:
Grant
Filed:
May 16, 2005
Date of Patent:
May 8, 2012
Assignee:
The University of North Carolina at Chapel Hill
Inventors:
Michael F. Goy, Nicholas G. Moss, Xun Qian
Abstract: The present invention relates to a pharmaceutical composition for preventing/treating conditions associated with PAR-2. The present invention also relates to a method for preventing/treating the condition using the pharmaceutical composition and use for manufacturing the pharmaceutical composition.
Abstract: A composition is provided to prevent, limit the effects of, delay the onset of, or treat one or more of the causes, symptoms or complications of gestational hypertension, preeclampsia, eclampsia and/or intrauterine growth restriction. The composition comprises a therapeutically effective amount of an antibody that reacts immunologically with or binds digoxin and has a high dose of digoxin binding capacity as the active ingredient. There is also provided a method of preventing, limiting the effects of, delaying the onset of, or treating a cause, symptom or complication of gestational hypertension, preeclampsia, eclampsia or intrauterine growth restriction, comprising the step of administering to a mammal a composition comprising a therapeutically effective amount of an antibody that reacts immunologically with or binds digoxin and has a high dose of digoxin binding capacity.
Abstract: Peptides that act as GC-C receptor agonists and contain at least one D-cys and are useful for the treatment of diuresis and heart disease as well as other disorders are described.
Type:
Application
Filed:
February 26, 2008
Publication date:
February 16, 2012
Inventors:
Daniel Zimmer, Angelika Fretzen, Mark Currie, G. Todd Milne
Abstract: The present invention relates to novel analogues of neuropeptide Y, pharmaceutical compositions containing the same, pharmaceutical formulations containing the same, and method of treating diseases or conditions mediated by neuropeptide Y-receptor binding. More particularly, the present invention relates to novel analogues of neuropeptide Y having proline substitution at position 34 and other substitution(s) as defined herein that selectively bind to the neuropeptide Y1 receptor subtype compared to the neuropeptide Y2 receptor subtype.
Abstract: The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid, and at least one bioactive agent for treating wet AMD. The nanoparticles are characterized with a positive surface charge and their enhanced permeability for paracellular drug delivery.
Type:
Grant
Filed:
July 26, 2007
Date of Patent:
February 14, 2012
Assignees:
GP Medical, Inc., National Tsing Hua University
Abstract: Chimeric therapeutics are disclosed that include a modified viral core protein and a nucleic acid bound to the modified viral core protein. The nucleic acid may be substantially homologous to a specific gene target. In some embodiments, the nucleic acid bound to the modified viral core protein is substantially non-immunogenic. Also disclosed are particles and compositions that include disclosec chimeric therapeutics.
Type:
Application
Filed:
April 8, 2011
Publication date:
December 1, 2011
Inventors:
Miguel de los Rios, John Mendlein, Timothy L. Bullock, Kenneth J. Oh, Patrick T. Johnson, Jacek Ostrowski, Stephanie de los Rios
Abstract: A protein scaffold based on a consensus sequence of fibronectin type III (FN3) proteins, such as the tenth FN3 repeat from human fibronectin (human Tenascin), including isolated nucleic acids that encode a protein scaffold, vectors, host cells, and methods of making and using thereof, exhibit enhanced thermal and chemical stability while presenting six modifiable loop domains which can be engineered to form a binding partner capable of binding to a target for applications in diagnostic and/or therapeutic compositions, methods and devices.
Abstract: Described herein are peptide compositions of a prominin-1, which have regenerative activity. As such the peptides are useful when regeneration is needed, for example, to enhance angiogenesis, increase VEGF binding to endothelial cells, promote vasodilation, enhance cell migration, enhance cell proliferation, stimulate neuronal growth, prevent neurodegeneration, and/or promote neuroregeneration.
Abstract: A method for treating a patient suffering from one of septic shock, acute kidney injury, severe hypotension, cardiac arrest, and refractory hypotension, but not from myocardial infarction, is provided. The method includes administering a therapeutically effective dose of Angiotensin II, or Ang II, to the patient.
Abstract: The invention describes compositions of peptide analogs exemplified by peptides derived from vasopressin, terlipressin, and GLP1 and others that are active in blood or cleavable in blood to release an active peptide. The peptide analogs have a general formula: A-(Cm)x-Peptide, wherein A is a hydrophobic moiety or a metal binding moiety, and Cm is a cleavable moiety consisting of glycine or alanine or lysine or arginine or N-Arginine or N-lysine, wherein x is an integer between 0-6 and N may be any amino acid or none. A may be linked to Cm by a linker group. The peptide analogs are complexed with polymeric carrier to provide enhanced half-life.
Type:
Grant
Filed:
July 31, 2008
Date of Patent:
June 14, 2011
Assignee:
PharmaIN Corporation
Inventors:
Gerardo M. Castillo, Elijah M. Bolotin, Elaine K. Chan
Abstract: Disclosed are peptide ligands for G-protein coupled receptors that are useful for treating disorders associated with G-protein coupled receptor activation.
Type:
Application
Filed:
December 14, 2010
Publication date:
May 5, 2011
Inventors:
Yossi Cohen, Ronen Shemesh, Amir Toporik, Zurit Levine, Assaf Wool, Dvir Dahary, Iris Hecht, Galit Rotman, Michal Ayalon-Soffer
Abstract: Methods are provided for treating a subject for a condition. In accordance with the subject methods, at least a portion of a subject's autonomic nervous system is modulated during at least one predetermined phase of the subject's menstrual cycle to alter the parasympathetic activity/sympathetic activity ratio in a manner that is effective to treat the subject for the condition. The subject methods find use in the treatment of a variety of different conditions, including various disease conditions, that increase in severity and/or occurrence during one or more phases of the menstrual cycle. Also provided are systems and kits for use in practicing the subject methods.
Type:
Grant
Filed:
May 13, 2004
Date of Patent:
March 1, 2011
Assignee:
Palo Alto Investors
Inventors:
Anthony Joonkyoo Yun, Patrick Yuarn-Bor Lee
Abstract: Peptides that act as GC-C receptor agonists and contain at least one D-cys and are useful for the treatment of diuresis and heart disease as well as other disorders are described.
Type:
Application
Filed:
February 26, 2008
Publication date:
January 27, 2011
Inventors:
Daniel Zimmer, Angelika Fretzen, Mark Currie, G. Todd Milne
Abstract: The present invention relates in one embodiment to PAPP-A exosite(s) interactors such as antibodies which bind to a region comprising LNR3 of PAPP-A and efficiently inhibit proteolysis of IGFBP-4, but not -5. The region comprising LNR3 represents a substrate binding exosite, which can be targeted for selective proteolytic inhibition. Accordingly, the present invention relates in one embodiment to differential inhibition of natural protease substrates by exosite targeting.
Type:
Application
Filed:
January 23, 2009
Publication date:
December 9, 2010
Inventors:
Claus Oxvig, Jakob Hauge Mikkelsen, Claus Gyrup Nielsen
Abstract: Novel biodegradable compositions are disclosed. The biodegradable compositions include at least one hydroxyl-terminated component and at least one bioactive peptide in a linear chain. The compositions may be utilized as medical devices including drug delivery devices, tissue adhesives and/or sealants.
Abstract: The present invention relates to nucleotide sequences, including expressed sequence tags (ESTs), oligonucleotide probes, polypeptides, vectors and host cells expressing, and immunoadhesions and antibodies to mammalian GFR?3, a novel ?-subunit receptor of the GDNF (i.e. GFR) receptor family. It further relates to an assay for measuring activation of an ?-subunit receptor by detecting tyrosine kinase receptor activation (i.e., autophosphorylation) or other activities related to ligand-induced ?-subunit receptor homo-dimerization or homo-oligomerization.
Type:
Application
Filed:
February 2, 2010
Publication date:
September 30, 2010
Inventors:
Frederic J. de Sauvage, Robert D. Klein, Heidi S. Phillips, Arnon Rosenthal